In vitro chemical testing generates release, stability, and bioaccessibility data, enabling informed formulation decisions across nutraceutical, pharmaceutical, and cosmeceutical product development pipelines. This reduces development uncertainty, supports faster optimisation of dosage forms, and strengthens technical confidence before scale-up, validation, and regulatory submission stages.

The INFOGEST model simulates human digestion conditions across salivary, gastric, and intestinal phases, enabling realistic evaluation of liposomal stability and release behaviour. It helps predict oral bioavailability, validate formulation performance under physiological conditions, and support scientifically substantiated claims for product positioning and regulatory documentation.

Dialysis and simulated digestion studies quantify controlled release behaviour, enabling clear differentiation between liposomal systems and conventional formulations in performance-driven markets. This supports claims of sustained delivery, improved absorption, and enhanced functionality, strengthening product positioning across competitive nutraceutical and pharmaceutical segments globally.

LipoEdge provides integrated in vitro testing using validated digestion models, diffusion systems, and antioxidant assays to ensure reliable and reproducible analytical outcomes. It enables clients to generate regulatory-aligned data, optimise formulations effectively, and accelerate product development timelines with strong technical and commercial confidence.

LipoEdge combines formulation understanding with analytical expertise, enabling customised study designs tailored to liposomal, nanosomal, and encapsulated delivery systems across applications. This ensures deeper insight into product behaviour, improved interpretation of results, and stronger alignment between laboratory findings and real-world product performance expectations.